Veracyte/$VCYT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Veracyte
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Ticker
$VCYT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
824
ISIN
US92337F1075
Website
Veracyte Metrics
BasicAdvanced
$2.2B
66.64
$0.41
2.15
-
Price and volume
Market cap
$2.2B
Beta
2.15
52-week high
$47.32
52-week low
$19.73
Average daily volume
1.1M
Financial strength
Current ratio
5.1
Quick ratio
4.541
Long term debt to equity
3.606
Total debt to equity
4.226
Interest coverage (TTM)
19,524.50%
Management effectiveness
Return on assets (TTM)
1.55%
Return on equity (TTM)
2.86%
Valuation
Price to earnings (TTM)
66.644
Price to revenue (TTM)
4.606
Price to book
1.8
Price to tangible book (TTM)
6.31
Price to free cash flow (TTM)
27.205
Growth
Revenue change (TTM)
23.42%
Earnings per share change (TTM)
-144.54%
3-year revenue growth (CAGR)
22.74%
3-year earnings per share growth (CAGR)
-15.61%
What the Analysts think about Veracyte
Analyst ratings (Buy, Hold, Sell) for Veracyte stock.
Veracyte Financial Performance
Revenues and expenses
Veracyte Earnings Performance
Company profitability
Veracyte News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Veracyte stock?
Veracyte (VCYT) has a market cap of $2.2B as of May 23, 2025.
What is the P/E ratio for Veracyte stock?
The price to earnings (P/E) ratio for Veracyte (VCYT) stock is 66.64 as of May 23, 2025.
Does Veracyte stock pay dividends?
No, Veracyte (VCYT) stock does not pay dividends to its shareholders as of May 23, 2025.
When is the next Veracyte dividend payment date?
Veracyte (VCYT) stock does not pay dividends to its shareholders.
What is the beta indicator for Veracyte?
Veracyte (VCYT) has a beta rating of 2.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.